Related Experiment Videos
Biopsy in indeterminate intraocular tumors
Nikolaos E Bechrakis1, Michael H Foerster, Norbert Bornfeld
1Department of Ophthalmology, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany. bechrakis@medizin.fu-berlin.de
Ophthalmology
|February 5, 2002
Summary
This study introduces an intraocular biopsy technique using a vitreous cutter for accurate diagnosis of uveal tumors. The method achieved a 97% diagnostic success rate, improving accuracy and avoiding risks associated with other biopsy methods.
Area of Science:
- Ophthalmology
- Oncology
- Surgical Pathology
Background:
- Uveal tumors often present diagnostic challenges, necessitating advanced histopathologic evaluation.
- Accurate diagnosis is crucial for appropriate treatment and prognosis of intraocular malignancies.
Purpose of the Study:
- To describe and evaluate an intraocular biopsy technique utilizing a vitreous cutter.
- To assess the diagnostic accuracy of this technique for clinically unclassifiable uveal tumors.
Main Methods:
- A retrospective case series involving intraocular biopsies performed with a vitreous cutter.
- Techniques included a two-port clear cornea approach for iris tumors and three-port pars plana vitrectomy for choroidal tumors.
- Specimens underwent standard formalin fixation, paraffin processing, and histopathologic staining, with immunohistochemistry for difficult cases.
Main Results:
- A definitive histopathologic diagnosis was achieved in 97% of cases (33/34).
- Melanoma was diagnosed in 73% of iris tumors and 57% of posterior intraocular tumors.
- Other diagnoses included nevus, metastasis, and vasoproliferative tumors. Complications were infrequent, and no increased tumor-related mortality was observed.
Conclusions:
- Intraocular biopsy with a vitreous cutter provides accurate histopathologic diagnosis of uveal tumors.
- This technique allows examination of formalin-fixed, paraffin-embedded tissue, enhancing diagnostic yield.
- It offers a safer alternative to transscleral biopsy, mitigating the risk of extraocular tumor spread.